Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
Background: Contemporary antiplatelet treatment in acute myocardial infarction (AMI) is based on one of two P2Y12 receptor inhibitors, prasugrel or ticagrelor. The aim of this study was to compare diurnal variability of platelet reactivity between patients receiving prasugrel and ticagrelor during t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/4/1124 |
| _version_ | 1797479011039838208 |
|---|---|
| author | Piotr Adamski Malwina Barańska Małgorzata Ostrowska Wiktor Kuliczkowski Katarzyna Buszko Katarzyna Kościelska-Kasprzak Bożena Karolko Andrzej Mysiak Jacek Kubica |
| author_facet | Piotr Adamski Malwina Barańska Małgorzata Ostrowska Wiktor Kuliczkowski Katarzyna Buszko Katarzyna Kościelska-Kasprzak Bożena Karolko Andrzej Mysiak Jacek Kubica |
| author_sort | Piotr Adamski |
| collection | DOAJ |
| description | Background: Contemporary antiplatelet treatment in acute myocardial infarction (AMI) is based on one of two P2Y12 receptor inhibitors, prasugrel or ticagrelor. The aim of this study was to compare diurnal variability of platelet reactivity between patients receiving prasugrel and ticagrelor during the initial phase of maintenance treatment after AMI. Methods: It was a prospective, two-center, pharmacodynamic, observational study. Blood for platelet testing was sampled at four time points on day four after AMI (8:00, 12:00, 16:00, 20:00). Diurnal variability of platelet reactivity was expressed as a coefficient of variation (CV) of the above-mentioned measurements. Results: 73 invasively-treated patients were enrolled (ticagrelor: <i>n</i> = 47, prasugrel: <i>n</i> = 26). CV was greater in patients treated with ticagrelor compared with prasugrel according to a VASP assay (47.8 [31.6–64.6]% vs. 21.3 [12.9–25.5]%, <i>p</i> < 0.001), while no statistical differences were detected when the CVs of platelet aggregation according to Multiplate were compared between ticagrelor- and prasugrel-treated patients. Ticagrelor-treated patients showed more pronounced platelet inhibition than prasugrel at 16:00 and 20:00 (VASP<sub>16:00</sub>: 20.6 ± 15.0 vs. 24.9 ± 12.8 PRI, <i>p</i> = 0.049; VASP<sub>20:00</sub>: 18.6 ± 17.7 vs. 26.0 ± 11.7 PRI, <i>p</i> = 0.002). Conclusions: Ticagrelor shows greater diurnal variability in platelet aggregation than prasugrel during the initial maintenance phase of AMI treatment, and this is due to the continuous increase of platelet inhibition after the morning maintenance dose. Both drugs provide an adequate antiplatelet effect early after AMI. Evaluation of the clinical significance of these findings warrants further investigation. |
| first_indexed | 2024-03-09T21:39:47Z |
| format | Article |
| id | doaj.art-00247d1694db4d9781925fc55f45907d |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T21:39:47Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-00247d1694db4d9781925fc55f45907d2023-11-23T20:32:01ZengMDPI AGJournal of Clinical Medicine2077-03832022-02-01114112410.3390/jcm11041124Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and TicagrelorPiotr Adamski0Malwina Barańska1Małgorzata Ostrowska2Wiktor Kuliczkowski3Katarzyna Buszko4Katarzyna Kościelska-Kasprzak5Bożena Karolko6Andrzej Mysiak7Jacek Kubica8Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandDepartment of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandDepartment of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandInstitute for Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, PolandDepartment of Theoretical Foundations of Biomedical Science and Medical Informatics, Collegium Medicum, Nicolaus Copernicus University, 87-067 Bydgoszcz, PolandDepartment and Clinic of Nephrology and Transplantation Medicine, Wroclaw Medical University, 50-367 Wroclaw, PolandInstitute for Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, PolandInstitute for Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, PolandDepartment of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, PolandBackground: Contemporary antiplatelet treatment in acute myocardial infarction (AMI) is based on one of two P2Y12 receptor inhibitors, prasugrel or ticagrelor. The aim of this study was to compare diurnal variability of platelet reactivity between patients receiving prasugrel and ticagrelor during the initial phase of maintenance treatment after AMI. Methods: It was a prospective, two-center, pharmacodynamic, observational study. Blood for platelet testing was sampled at four time points on day four after AMI (8:00, 12:00, 16:00, 20:00). Diurnal variability of platelet reactivity was expressed as a coefficient of variation (CV) of the above-mentioned measurements. Results: 73 invasively-treated patients were enrolled (ticagrelor: <i>n</i> = 47, prasugrel: <i>n</i> = 26). CV was greater in patients treated with ticagrelor compared with prasugrel according to a VASP assay (47.8 [31.6–64.6]% vs. 21.3 [12.9–25.5]%, <i>p</i> < 0.001), while no statistical differences were detected when the CVs of platelet aggregation according to Multiplate were compared between ticagrelor- and prasugrel-treated patients. Ticagrelor-treated patients showed more pronounced platelet inhibition than prasugrel at 16:00 and 20:00 (VASP<sub>16:00</sub>: 20.6 ± 15.0 vs. 24.9 ± 12.8 PRI, <i>p</i> = 0.049; VASP<sub>20:00</sub>: 18.6 ± 17.7 vs. 26.0 ± 11.7 PRI, <i>p</i> = 0.002). Conclusions: Ticagrelor shows greater diurnal variability in platelet aggregation than prasugrel during the initial maintenance phase of AMI treatment, and this is due to the continuous increase of platelet inhibition after the morning maintenance dose. Both drugs provide an adequate antiplatelet effect early after AMI. Evaluation of the clinical significance of these findings warrants further investigation.https://www.mdpi.com/2077-0383/11/4/1124myocardial infarctionplatelet aggregation variabilityprasugrelticagrelor |
| spellingShingle | Piotr Adamski Malwina Barańska Małgorzata Ostrowska Wiktor Kuliczkowski Katarzyna Buszko Katarzyna Kościelska-Kasprzak Bożena Karolko Andrzej Mysiak Jacek Kubica Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor Journal of Clinical Medicine myocardial infarction platelet aggregation variability prasugrel ticagrelor |
| title | Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor |
| title_full | Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor |
| title_fullStr | Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor |
| title_full_unstemmed | Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor |
| title_short | Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor |
| title_sort | diurnal variability of platelet aggregation in patients with myocardial infarction treated with prasugrel and ticagrelor |
| topic | myocardial infarction platelet aggregation variability prasugrel ticagrelor |
| url | https://www.mdpi.com/2077-0383/11/4/1124 |
| work_keys_str_mv | AT piotradamski diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor AT malwinabaranska diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor AT małgorzataostrowska diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor AT wiktorkuliczkowski diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor AT katarzynabuszko diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor AT katarzynakoscielskakasprzak diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor AT bozenakarolko diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor AT andrzejmysiak diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor AT jacekkubica diurnalvariabilityofplateletaggregationinpatientswithmyocardialinfarctiontreatedwithprasugrelandticagrelor |